首页> 美国卫生研究院文献>Case Reports in Otolaryngology >Optimal Postoperative Treatment for Composite Laryngeal Small Cell Carcinoma
【2h】

Optimal Postoperative Treatment for Composite Laryngeal Small Cell Carcinoma

机译:复合型喉小细胞癌的最佳术后治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Small cell carcinoma (SmCC) most commonly occurs in the lung and rarely arises from the head and neck region. Further, composite SmCC is extremely rare. Therefore, no postoperative treatment strategy has been established. We report a 59-year-old male patient referred to our outpatient clinic for further examination and treatment of a laryngeal tumor. Biopsy from the tumor revealed squamous cell carcinoma (SCC). The preoperative diagnosis was supraglottic SCC (T3N2bM0), and total laryngectomy and bilateral neck dissection were performed. Pathological examination revealed 2 individual cancer components: SmCC and SCC. Postoperative chemoradiotherapy (2 courses of cisplatin (CDDP) and etoposide (VP-16)) was indicated. Following the postoperative chemoradiotherapy, 2 courses of adjuvant chemotherapy were administered. The patient is currently alive with no evidence of disease at 36 months following the completion of therapy. Postoperative chemoradiotherapy and adjuvant chemotherapy are optimal treatment strategies for laryngeal composite SmCC.
机译:小细胞癌(SmCC)最常见于肺,很少发生于头颈部。此外,复合SmCC非常罕见。因此,尚未建立术后治疗策略。我们报告了一名59岁的男性患者,转诊至我们的门诊诊所进一步检查和治疗了喉部肿瘤。肿瘤活检显示鳞状细胞癌(SCC)。术前诊断为声门上SCC(T3N2bM0),并行全喉切除术和双侧颈清扫术。病理检查发现2个单独的癌症成分:SmCC和SCC。术后放化疗(2疗程的顺铂(CDDP)和依托泊苷(VP-16))被指示。术后放化疗后,进行了2个疗程的辅助化疗。该患者在完成治疗后的36个月内尚无疾病迹象。术后放化疗和辅助化疗是喉复合SmCC的最佳治疗策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号